Verastem ROA

Mitä Verastem tekee? Verastem Oncology develops and commercializes oncology drugs to improve cancer patient survival and quality of life. The company focuses on defactinib, an oral small molecule inhibitor of FAK and PYK2, and VS-6766, a RAF/MEK pathway inhibitor. Defactinib is being evaluated for combination therapy in solid tumors, while VS-6766 blocks MEK kinase activity and RAF phosphorylation. Verastem conducts clinical trials for cancers with limited treatment options including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer, and pancreatic cancer. The company markets and develops these products for healthcare providers and patients in the oncology segment. Verastem Oncology targets cancer patients requiring new treatment options, particularly in underserved areas like pancreatic cancer and mesothelioma. Its products are designed to address unmet medical needs in oncology through targeted therapies. Verastem generates revenue through the commercialization of defactinib and VS-6766 once approved. The company's business model relies on developing drugs for cancer treatment, with clinical trials focused on improving outcomes for patients with limited therapeutic options. Revenue streams come from product sales and potential partnerships for drug development and commercialization. Verastem on yksi Eurpooliin suosituimmista yhtiöistä.